TiTAN, BIOLOGICALLY ACTIVE, stent provides a rate of MACE (Major Adverse Cardiac Event) at 1 year of the same magnitude or non-inferior compared with that of PHARMACOLOGICALLY active stents but associated with a better safety profile (AMI, Death and Thrombosis), a trend that increases over time to achieve at 5 years differences that have become significant in terms of SAFETY.